PMID: 24591144
Question: Are the elderly with oropharyngeal carcinoma undertreated?
Correct Answer: maybe

======================= Launch the MCC process =======================
PMID: 24591144
Question: Are the elderly with oropharyngeal carcinoma undertreated?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- The core question is whether elderly patients with oropharyngeal squamous cell carcinoma (OPSCC) are receiving less treatment compared to younger patients, which would indicate undertreatment.
- Key information to look for includes treatment rates across different age groups and the benefits of treatment in elderly populations.

**2. Evidence Evaluation**
- The study analyzed 14,909 OPSCC patients from the SEER database (2004-2009) across various age groups.
- Findings show a significant increase in the number of elderly patients (age 55 and older) not receiving treatment (surgery, radiation, or combined therapy).
- Kaplan-Meier analysis revealed that age groups 65-74 and 75-84 benefitted significantly in disease-specific survival (DSS) from aggressive treatments.
- Multivariate analysis did not show a significant difference in hazard ratios for combined treatment among the age groups 45-54, 55-64, 65-74, and 75-84, suggesting that elderly patients could handle aggressive treatments similarly to younger patients.
- The abstract concludes that fewer elderly patients are being treated proportionally and recommends objective measures to assess fitness, implying potential undertreatment.

**3. Conclusion**
- The evidence indicates that elderly patients are less likely to receive aggressive treatments despite benefiting from them, which suggests undertreatment.

**4. Final Answer**
**My final choice is: "yes"**
GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether elderly patients with oropharyngeal carcinoma (OPSCC) are undertreated. Key information to assess includes treatment rates across age groups, survival outcomes with treatment, and whether older patients receive less aggressive therapy compared to younger patients.  

**2. Evidence Evaluation**  
- **Treatment Rates**: The abstract states that "proportionally fewer elderly patients with OPSCC are being treated than younger individuals," with a significant increase in untreated patients after age 55. This directly supports undertreatment in older age groups.  
- **Survival Benefits**: Kaplan-Meier analysis showed that even older age groups (65–74 and 75–84 years) had "substantial benefits in disease-specific survival (DSS)" with surgery, radiation, or combined therapy. This indicates that treatments are effective in elderly patients.  
- **Multivariate Analysis**: The lack of statistically significant differences in hazard ratios for combined treatment across age groups (45–54 to 75–84) suggests that treatment efficacy is comparable in older and younger patients.  
- **Conclusion of the Study**: The authors explicitly recommend reducing undertreatment in the elderly via objective fitness assessments, reinforcing the idea that undertreatment exists.  

The evidence is strong and directly relevant, as the study uses a large population database and survival analysis to address undertreatment and its consequences.  

**3. Conclusion**  
The study provides clear evidence that elderly patients with OPSCC are undertreated (proportionally fewer receive therapy after age 55) despite comparable survival benefits from aggressive treatments. The authors’ recommendation to address undertreatment further supports this conclusion.  

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether elderly patients with oropharyngeal carcinoma (OPSCC) are undertreated. Key information to assess includes:  
- Treatment rates across age groups.  
- Survival outcomes for elderly patients who received aggressive therapy.  
- Whether age alone explains treatment disparities or if other factors (e.g., comorbidities) are involved.  

**2. Evidence Evaluation**  
- **Treatment Disparities**: The study found a significant increase in untreated patients after age 55, with fewer elderly receiving surgery, radiation, or combined therapy.  
- **Survival Benefit**: Kaplan-Meier analysis demonstrated substantial disease-specific survival (DSS) benefits for elderly patients (65–84 years) treated with aggressive therapies.  
- **Multivariate Analysis**: No significant difference in hazard ratios for combined treatment efficacy across age groups ≤84, suggesting comparable treatment effectiveness in younger and elderly patients.  
- **Limitations**: Retrospective design (potential confounding factors like comorbidities unaccounted for), but the authors emphasize using objective fitness assessments rather than age alone to guide treatment.  

**3. Conclusion**  
The evidence supports that elderly OPSCC patients receive less treatment despite deriving survival benefits comparable to younger patients. The disparity in treatment rates, combined with demonstrated efficacy, suggests undertreatment driven by age-based biases rather than objective fitness.  

**4. Final Answer**  
**My final choice is: "yes"**
DeepSeek selected: yes

Initial consensus: All models selected yes